This facility, which will be built on a three-story scale (gross floor area 3,966 m 2 ), is scheduled to be completed in March 2021. The facility will be equipped with plant incubating facilities such as tobacco and rice cell culture, which can be used by bio-venture companies, and will secure air pressure facilities, air conditioning facilities and sterilization facilities to prevent the outflow of genetically modified materials. In addition, the vaccine production facility will establish industrial facilities for production of plant-derived vaccines such as protein extraction, protein purification equipment, and others. It will also have animal bleeding facilities and efficacy assessment facilities to verify the effectiveness and toxicity of the vaccine developed, as well as offices, research labs, and conference rooms that bio-venture companies can use starting at June 2021.
Pohang Techno Park Foundation, which is in charge of this project, plans to strengthen its customized support for each company through 1:1 Project Manager (PM) designation, plan R&D and non R&D projects by government and local governments, and support for clinical trials, licensing and certification of plant-derived pharmaceuticals in order to concentrate domestic bio-venture companies in Pohang Fusion Technology Industry Zone. In addition, Gyeongbuk Province and Pohang city are planning national projects, attracting companies, and raising funds for bio-venture companies in order to foster plant-derived vaccine industry, as well as plant-derived pharmaceuticals and recombinant protein industries. In the future, Pohang city plans to strategically foster a promising bio-industry that will contribute to the future safety community through the creation of a regional cluster of plant-based Bio-venture Town Complex.
